公开(公告)号：EP3278812A1

公开(公告)日：2018-02-07

申请号：EP16771815.4

申请日：2016-01-12

申请人： National Institute of Advanced Industrial Science and Technology ,  Hokusan Co. Ltd.

发明人： ITO, Akira ,  MATSUMURA, Takeshi ,  GOTANDA, Toru ,  TABAYASHI, Noriko ,  ITCHODA, Noriko ,  AOKI, Takashi ,  KAGAYA, Uiko

IPC分类号： A61K38/21 ,  A61K9/20 ,  A61K9/68 ,  A61P27/16 ,  A61P29/00

CPC分类号： A61K9/20 ,  A23L33/00 ,  A61K38/212 ,  A61P27/16

摘要： The object of the present invention is to provide a therapeutic agent illustrating an immediate and sustained effect on chronic intractable external otitis. The present invention provide a composition, pharmaceutical composition, food and feed for preventing and/or treating chronic intractable external otitis, each comprising interferon-α (IFNα) as an active ingredient. Orally administering the composition of the present invention can provide inhibition, alleviation, treatment and prevention for chronic intractable external otitis. According to the present invention, IFNα can give a sufficient effect even when administered in a very small amount.

摘要翻译： 本发明的目的是提供说明对慢性顽固性外耳炎立即和持续作用的治疗剂。 本发明提供了用于预防和/或治疗慢性顽固性外耳炎的组合物，药物组合物，食品和饲料，各自包含干扰素-α（IFNα）作为活性成分。 口服本发明的组合物可以为慢性顽固性外耳炎提供抑制，减轻，治疗和预防。 根据本发明，即使以非常少的量给药，IFNα也能够产生充分的效果。

公开(公告)号：EP3508216A1

公开(公告)日：2019-07-10

申请号：EP17846744.5

申请日：2017-09-04

申请人： Hokusan Co. Ltd. ,  National Institute of Advanced Industrial Science and Technology ,  School Juridical Person The Kitasato Institute

发明人： TABAYASHI, Noriko ,  GOTANDA, Toru ,  SASAKI, Hanae ,  ITCHODA, Noriko ,  KAGAYA, Uiko ,  MATSUMURA, Takeshi ,  ITO, Akira ,  IKADAI, Hiromi

IPC分类号： A61K39/015 ,  C07K14/445 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09

摘要： It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine.
The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.